Online: | |
Visits: | |
Stories: |
Story Views | |
Now: | |
Last Hour: | |
Last 24 Hours: | |
Total: |
The results of a study led by researchers at the Johns Hopkins Bloomberg School of Public Health could lead to new follow-up protocols for oropharyngeal cancer patients.
Cancer in the oropharynx is responsible for almost 3% percent of new cancers in the United States.
In a study among 67 oropharyngeal cancer patients, traces of HPV16 DNA in their oral rinse after treatment showed up in five cases. In these cases, the cancer recurred. However, most of the recurred cancer was localized to the oropharynx (the walls of the throat, back of the tongue, tonsils, and the soft palate) and had spread to other regions of the body.
The fact that all of the patients who had HPV16 DNA in their rinses after treatment, went on to have a relapse of the malignancy, means that the post-treatment detection of HPV16 DNA is very significant for prognosis, said researchers.